Biomerica's Fortel Ulcer Test Approved For Sale In UAE, Enabling Rapid 10-Minute Detection Of Helicobacter pylori, A Class 1 Carcinogen Linked To 80% Of Gastric Cancer Cases—Offering Fast, Accessible Diagnostic Tool Amid Growing Regional GI Health Concerns

Author: Benzinga Newsdesk | April 23, 2025 08:20am

• 10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancer
• Approximately 80% of gastric cancer cases are linked to H. pylori infection; WHO classifies H. pylori as a Class 1 carcinogen
• This test empowers healthcare providers with fast, accessible testing across the UAE
  
   

IRVINE, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:BMRA), a global provider of advanced diagnostic solutions, announced today that its Fortel® Ulcer Test has been approved for sale by the United Arab Emirates (UAE) Ministry of Health and Prevention. This regulatory approval enables Biomerica to introduce its rapid point-of-care test for Helicobacter pylori (H. pylori) infection across the UAE—a region where gastrointestinal diseases are a growing public health concern.

The Fortel® Ulcer Test is a simple, quick and user-friendly diagnostic tool that detects antibodies to H. pylori, a bacterium known to cause peptic ulcer disease, dyspepsia, and gastric cancer. The test delivers accurate results in just 10 minutes.

Posted In: BMRA